CHINARES PHARMA(HK:03320) 智通财经网·2025-10-30 00:12Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners, all of which are subsidiaries of the company [1] - The total commitment from the group will be RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic development direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key related areas [1] - The fund is expected to enhance investment channels in the synthetic biology industry, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1]